ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: PUB069

Fibrillary Glomerulonephritis

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Author

  • Farran, Abdulkader, Ascension Michigan, Warren, Michigan, United States
Introduction

AGE: 68 GENDER: Female ALLERGIES: None BP at Home: SBP 140-150s.
PMH: HTN,OSA,COPD,CHpEF. Review of labs shows evidence of volume depletion in the past, hyaline casts.
SH: tobacco use
Current Meds: Losartan, Diltiazam, Lasix, Metolazon
Worsening renal disease.
Physical exam:
Bilateral Pitting edema , Irregular rhythm
5.6 bun31 Cr 2.87 glucose113 GFR 18ml/min, CL 101 uric acid 4.4 Ca 8.4 phos 3.3, includes holding ARB therapy, renal ultrasound, UACR,

Case Description

Next follow up visit:
The patient's lab results show a worsening anemia and a need for an urgent kidney biopsy. Kidney ultrasound showed no hydronephrosis with R 9.5 cm, L 9 cm kidney. The cause of the condition remains unknown.

Hospital course:
The patient was prescribed IV steroid pulse for three days and received two units of PRBC. Urgent biopsy was held, and GI consultation was conducted. EGD/ colonoscopy showed only polyp which was removed with no malignancy, serology work up was negative. EGD/ colonoscopy showed was negative, serology work up was negative.

Discussion

Fibrillary glomerulonephritis is a condition characterized by hematuria, proteinuria, kidney function impairment, hypertension, and monoclonal gammopathy. Diagnosis involves kidney biopsy, electrophoresis, immunofixation, serum free light chain levels, and other tests. Patients without known cancer should undergo age and risk appropriate cancer screening, while those with imamunotactoid glomerulopathy should be screened for monoclonal gammopathy.

Management approach:
Addressing underlying causes, immunosuppressive therapy, and supportive care.